Photo by Sam Ogden and courtesy of the Dana-Farber Cancer Institute
The trial supported by the Soupy for Loopy Foundation will use bevacizumab (AvastinTM) and zoledronic acid (Zometa®) with low doses of the chemotherapeutic agent cyclophosphamide (cytoxan). Referred to as N0702, this combination of new and standard agents will likely have anti-angiogenic activity, stopping the growth of tumor blood vessels, especially in metastatic bone sites. Although bevacizumab is proven to be an active agent in many adult tumors and zoledronic acid has been shown to prevent adult cancer related bone events, the challenge for pediatricians is trying to determine how and when to use these agents in children with diseases like neuroblastoma. These funds, which were raised through general donations and various fundraising events, will be instrumental in helping NANT get the N0702 study open at the institutions faster, so that it is available sooner. For children with neuroblastoma, we know firsthand that time is truly an important element in giving hope to families when there is nothing left to try.
Funds will support Neuroblastoma Clinical Trial N0702 and help to get the study open faster so that it is available to the children sooner.
Copyright 2007-2018 Soupy for Loopy Foundation, Inc. All rights reserved.